Home » New Hemophilia Drug Gets FDA Nod
New Hemophilia Drug Gets FDA Nod
The FDA approved a new preventative treatment for hemophilia from Genentech.
The medication, Hemlibra (emicizumab-kxwh), is injected weekly to reduce the frequency of bleeding episodes in children and adults with hemophilia A with factor VIII inhibitors.
Hemlibra is a biologic designated as an orphan drug by the FDA. The use of the four-letter suffix follows a policy announced in January for branded biologics and biosimilars, with this usage one of the first for an approved biologic.
Upcoming Events
-
23Apr
-
25Apr
-
07May
-
14May
-
30May